HeartBeam

HeartBeam, Inc. is a development stage company, which engages in cardiovascular diagnostic technology. Its electrocardiogram (ECG) collection device provides physicians with cardiac diagnostic information for a patient that is outside of a medical institution. The device sends ECG signals to the patient's smartphone and on to a cloud-based software expert system. The company was founded by Branislav Vajdic in 2015 and is headquartered in Santa Clara, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

HeartBeam reports Q1 loss, eyes FDA clearances for growth

HeartBeam's Q1 2024 performance showed financial challenges but promising technological advancements
The company's focus on FDA clearances and AI development positions it for growth
Opportunities in remote cardiac monitoring and AI-driven healthcare present avenues for expansion
Balancing financial stability with innovation will be key for HeartBeam's future success

HeartBeam advances AIMIGo technology despite financial challenges

HeartBeam is making progress towards FDA clearance for its innovative cardiac monitoring device, AIMIGo.
Despite financial challenges, the company's strong IP protection and AI capabilities position it well for future growth.
Opportunities lie in expanding technology applications, gaining regulatory approval, and leveraging AI for automated diagnostics.

HeartBeam reports Q3 loss, progresses FDA review, and strengthens leadership

HeartBeam's Q3 2024 financials show a net loss of $4.979 million, with a focus on managing cash burn and aligning capital raising with milestones.
The company's core technology and clinical evidence position it well for FDA clearances and commercial launch preparations.
New management appointments bring leadership strength to drive HeartBeam's growth and innovation in cardiac care.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Reports Third Quarter and Nine Months 2021 Financial Results

HeartBeam Reports Third Quarter and Nine Months 2021 Financial Results

HeartBeam is pioneering a breakthrough ECG telemedicine solution. A credit card size device sends ECG recording to a cloud software enabling CVD diagnosis in ambulatory settings outside of a hospital.

HeartBeam: Cardiovascular Diagnostics On The Go

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Announces Closing of Initial Public Offering

HeartBeam Announces Closing of Initial Public Offering

A heart health innovator went public yesterday. Here's why you shouldn't be worried by the turbulence of the HeartBeam IPO.

HeartBeam IPO: Why BEAT Stock Has Investors' Hearts Racing Friday

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Announces Pricing of $16.5 Million Initial Public Offering

HeartBeam Announces Pricing of $16.5 Million Initial Public Offering

NEW ORLEANS--(BUSINESS WIRE)--Please replace the release dated December 23, 2020 with the following corrected version due to multiple revisions. The updated release reads: BIOTELEMETRY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioTelemetry, Inc. - BEAT Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating t

CORRECTING and REPLACING BIOTELEMETRY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioTelemetry, Inc. - BEAT

Royal Philips

Philips (PHG) enters into a deal to acquire BioTelemetry, which drives the expansion of its cardiac care portfolio and fuels customer acquisition.

Philips (PHG) Expands Portfolio With BioTelemetry Acquisition

NEW YORK, Dec. 19, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: BioTelemetry, Inc. (NASDAQ: BEAT) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Companies - BEAT, SNCA, BBIO, TLRY, NEOS

NEW YORK, Dec. 18, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of BioTelemetry, Inc. ("BioTelemetry" or the "Company") (NASDAQ: BEAT) in connection with the proposed acquisition of the Company...

SHAREHOLDER ALERT: WeissLaw LLP Investigates BioTelemetry, Inc.

NEW YORK, Dec. 18, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating BioTelemetry, Inc. ("BEAT" or the "Company") (BEAT) relating to its...

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of BioTelemetry, Inc. - BEAT

NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of BioTelemetry, Inc. (NASDAQ: BEAT) breached their fiduciary duties or violated the federal securities laws in connection with the company's acquisition by Koninklijke Philips N.V. (NYSE: PHG) (“Royal Philips”).

BIOTELEMETRY ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of BEAT and Encourages Investors to Contact the Firm

NEW YORK, Dec. 18, 2020 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by BioTelemetry, Inc. (NASDAQ: BEAT) and its board of directors concerning the proposed acquisition of the company by Royal Philips (NYSE: PHG). Stockholders will receive $72.00...

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of BioTelemetry, Inc.

BioTelemetry gained as much as 18% on Friday after news that the cardiac-diagnostics firm will be acquired by Dutch company Royal Philips for $2.8 billion. BioTelemetry is a Pennsylvania-based medical company that makes equipment that remotely diagnoses and monitors cardiac activity.

BioTelemetry soars 18% after Philips announces acquisition of cardiac-diagnostics company

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of BioTelemetry, Inc. (NASDAQ: BEAT) to Royal Philips for $72.00 per share in cash is fair to BioTelemetry shareholders. Halper Sadeh encourages BioTelemetry shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether B

BioTelemetry Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of BioTelemetry, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – BEAT

SAN DIEGO, Dec. 18, 2020 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of BioTelemetry, Inc. (NASDAQ: BEAT) breached their fiduciary duties in connection with the proposed sale of the Company to Royal Philips...

(BEAT) Alert: Johnson Fistel Investigates Proposed Sale of BioTelemetry; Is $72 a Fair Price?

MALVERN, Pa., Dec. 18, 2020 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ: BEAT) , the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today announced that they have entered into a definitive merger agreement with Royal Philips (NYSE: PHG, AEX: PHIA).

Philips to Acquire BioTelemetry

BioTelemetry has had a better than expected third quarter, leveraging new patient uptake plus clinician accounts in their healthcare and continuous care segments. Management have secured better lending terms on their revolving facility, and cash runaway is well over 2 years.

BioTelemetry Has Sequential Upside Via Double-Digit Growth Into 2021

BioTelemetry's (BEAT) CEO Joseph Capper on Q3 2020 Results - Earnings Call Transcript

BioTelemetry (BEAT) delivered earnings and revenue surprises of 15.38% and 7.96%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

BioTelemetry (BEAT) Q3 Earnings and Revenues Beat Estimates

Posts Record Quarterly Revenue Amidst Rapid Recovery Posts Record Quarterly Revenue Amidst Rapid Recovery

BioTelemetry, Inc. Reports Third Quarter 2020 Financial Results

MALVERN, Pa., Oct. 22, 2020 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT) will release its third quarter 2020 earnings on Thursday, October 29 at 4:00 PM Eastern Time.

BioTelemetry, Inc. to Release Third Quarter 2020 Earnings Results on October 29, 2020

BioTelemetry (BEAT) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

BioTelemetry (BEAT) Looks Good: Stock Adds 7.7% in Session

BioTelemetry's (BEAT) CEO Joseph Capper on Q2 2020 Results - Earnings Call Transcript

BioTelemetry (BEAT) delivered earnings and revenue surprises of 191.67% and 15.34%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

BioTelemetry (BEAT) Beats Q2 Earnings and Revenue Estimates

Posts Strong Results and Ramps Up Business Development Activity Posts Strong Results and Ramps Up Business Development Activity

News for HeartBeam Stock (BEAT)